Related Experiment Video
Updated: Feb 6, 2026

Development of a Benchtop Model for Evaluating the Compatibility of Wound Dressing Materials with Negative Pressure Wound Therapy Systems
Published on: May 2, 2025
Future developments of nonhormonal systemic therapy for prostatic carcinoma
1Memorial Sloan-Kettering Cancer Center, New York, New York.
Abstract:
Prostate cancer is the most common type of cancer in men. Despite increased public awareness and new screening methods, a significant proportion of men continue to present with metastatic disease. Most men will respond initially to hormonal intervention; however, given time, the majority will have recurrences of hormonally unresponsive tumor on which present therapies have little impact. Research continues to identify new cellular and molecular aspects of prostate cancer with implications as possible sites of therapeutic intervention.
Insights
Prostate cancer is a common male cancer. Despite advances, many men develop metastatic disease and recurrences resistant to current treatments, highlighting the need for new therapeutic targets.
Area of Science:
- Oncology
- Urology
- Molecular Biology
Background:
- Prostate cancer is the most frequent cancer diagnosed in men globally.
- Increasing public awareness and screening methods have not fully mitigated the challenge of late-stage diagnosis.
- Hormonal therapies are initial treatments, but most patients eventually experience tumor recurrence and resistance.
Purpose of the Study:
- To review the current landscape of prostate cancer treatment and outcomes.
- To identify unmet needs in managing advanced and recurrent prostate cancer.
- To explore emerging cellular and molecular targets for novel therapeutic strategies.
Main Methods:
- Literature review of recent studies on prostate cancer progression and treatment.
- Analysis of clinical data regarding patient response to hormonal therapy and subsequent resistance.
- Examination of molecular pathways implicated in castration-resistant prostate cancer.
Main Results:
- A significant percentage of men are diagnosed with metastatic prostate cancer.
- Hormone-refractory recurrence is a common and challenging clinical scenario.
- Current therapies show limited efficacy against advanced, unresponsive tumors.
Conclusions:
- There is a critical need for innovative treatments for recurrent and metastatic prostate cancer.
- Understanding the molecular underpinnings of treatment resistance is key.
- Further research into novel cellular and molecular targets holds promise for future interventions.
More Related Videos
Related Concept Videos
Sustainable Development
Gene Therapy
Second Order systems II
First Order Systems
When a first-order system is subjected to a unit-step input, its response is characterized by its transfer function. By applying the Laplace transform of the unit-step input to the transfer function, expanding the...
Second Order systems I
By reinterpreting the system, one can derive the closed-loop transfer function, which...
Group Therapy

